Long-term efficacy and safety of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): extended follow-up of an open-label, multicentre, randomised, non-inferiority trial.
Goodall RL, Nunn AJ, Meredith SK, Bayissa A, Bhatnagar AK, Chiang CY, Conradie F, Gopalan N, Gurumurthy M, Kirenga B, Kiria N, Meressa D, Moodliar R, Ngubane N, Rassool M, Sanders K, Solanki R, Squire SB, Teferi M, Torrea G, Tsogt B, Tudor E, Van Deun A, Rusen ID; STREAM study collaborators.
Goodall RL, et al. Among authors: meredith sk.
Lancet Respir Med. 2024 Oct 1:S2213-2600(24)00186-3. doi: 10.1016/S2213-2600(24)00186-3. Online ahead of print.
Lancet Respir Med. 2024.
PMID: 39366400
Free article.